Bladder Cancer Patient on Everolimus Has Complete Response
Cancer Network
In a phase I trial, a bladder cancer patient has had a 14-month complete response with the combination of the mTOR inhibitor everolimus and pazopanib, a selective multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis, including …
Patient with advanced bladder cancer shows complete response to everolimus …News-Medical.net
Exceptional Responder Provides Treatment Clues in Bladder CancerOncLive
Genomic testing links ‘exceptional’ drug response to rare mutations in bladder …EurekAlert (press release)

all 11 news articles »

Veloxis Pharmaceuticals A/S – US FDA Accepts Veloxis’ New Drug Application …
Wall Street Journal
Envarsus(R) is Veloxis’ once-daily tacrolimus based on the company’s proprietary MELTDOSE technology. Key points: — FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 3, 2014 — The NDA was submitted to the …
U.S. FDA Accepts Veloxis’ New Drug Application for Envarsus® for the …GlobeNewswire (press release)

all 6 news articles »

Study: Lower Corticosteroid Doses Might be Beneficial
TheHorse.com
Initial results of a study conducted at the University of Kentucky Gluck Equine Research Center suggest accepted dosage levels for several commonly used corticosteroids might be worth further study. At the Kentucky Equine Drug Research Council’s …

Patient with advanced bladder cancer shows complete response to everolimus …
News-Medical.net
A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have caused this exceptional …
Exceptional Responder Provides Treatment Clues in Bladder CancerOncLive
Genomic Testing Links “Exceptional” Drug Response to Rare Mutations in …Newswise (press release)
Genomic test ‘exceptional’ drug response for bladder cancerHealth and Beauty News (blog)

all 9 news articles »

Bladder cancer Pt with rare genetic mutations shows exceptional response to …
Science Codex
PHILADELPHIA — A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have …

and more »

Genomic testing links ‘exceptional’ drug response to rare mutations in bladder …
EurekAlert (press release)
BOSTON — A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, and genomic …

Bladder cancer Pt with rare genetic mutations shows exceptional response to …
EurekAlert (press release)
PHILADELPHIA — A patient with advanced bladder cancer experienced a complete response for 14 months to the drug combination everolimus and pazopanib in a phase I trial, and genomic profiling of his tumor revealed two alterations that may have …

Investigation Report on China Tacrolimus Market, 2009-2018
PR Newswire (press release)
Tacrolimus, also named as “”FK506″” and “”FR-900506″”, was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade …

and more »

Research and Markets: Investigation Report on China’s Tacrolimus Market, 2009 …
Fort Mills Times
Tacrolimus, also named as “”FK506″” and “”FR-900506″”, was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade …

and more »

Research and Markets: Investigation Report on China’s Tacrolimus Market, 2009 …
Business Wire (press release)
Tacrolimus, also named as “”FK506″” and “”FR-900506″”, was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade …

and more »